corona radiata bilaterally on the fluid-attenuated inversion recovery (FLAIR) sequences. Electromyography and nerve-conduction studies showed no abnormalities. Six weeks later, her leg symptoms had improved, but the patient reported new visual blurring in her right eye. The visual acuity of the right eye was 20/100, and that of the left was 20/15. Examination of cerebrospinal fluid in November 1999 showed 1 white cell per cubic millimeter, 55 mg of protein per deciliter, and normal values for glucose (64 mg per deciliter [3.6 mmol per liter]), IgG (3.2 mg per deciliter), the IgG index (0.57), and the IgGsynthesis rate (0.3 mg per 24 hours). No oligoclonal bands were detected in a specimen of cerebrospinal fluid that was concentrated by a factor of 80. Levels of vitamin B 12 and folate were normal, tests for antinuclear antibodies and anticentromere antibodies were negative, and thyroid-function tests were normal. A complete blood count was also normal, except for mild leukocytosis (11, 200 cells per cubic millimeter).
In January 2000, MRI showed two new nonenhancing parietal lesions with increased FLAIR signal and decreased T 1 -weighted signal. In February 2000, the patient reported that her vision was normal and that her right-sided numbness had nearly resolved. She began receiving 30 µg of interferon beta-1a intramuscularly each week, tizanidine, calcium, magnesium, and vitamins B, C, and E for presumed multiple sclerosis (Table 1) . In May 2000, she began taking tamsulosin for difficulty with bladder emptying and citalopram for depression.
In March 2001, the patient noted worsening vision, band-like paresthesias around her back and abdomen, and increasing weakness and spasticity of her legs. The strength of both legs was mildly decreased (4+/5), and her gait was slightly spastic, although her deep tendon reflexes were normal. She received 500 mg of methylprednisolone twice daily intravenously for five days (March 16 through 20, 2001) for a suspected exacerbation of multiple sclerosis. In September 2001, she reported some decline in fine motor skills in her hands and worsening spasticity in her legs as well as some decline in cognition, including short-term memory, and began taking donepezil. She had a score of 2.5 on the Kurtzke Expanded Disability Status Scale (EDSS) in March 2002 (range of scores, 0 to 10, with higher scores indicating a greater degree of disability).
In April 2002, the patient was enrolled in a randomized, placebo-controlled, parallel-group, multicenter study designed to determine the safety and efficacy of natalizumab combined with interferon beta-1a in patients with relapsing-remitting multiple sclerosis (the Biogen Idec and Elan 1802 SENTINEL trial). At the time of her enrollment, T 2 -weighted MRI showed approximately nine lesions and her EDSS score was 0. She continued to take 30 µg of interferon beta-1a intramuscularly weekly throughout the study. Additional medications at study entry included citalopram, rofecoxib, and tramadol in combination with acetaminophen.
During the study, the patient received a total of 30 doses of natalizumab (300 mg, or approximate- In November 2004, the patient reported new problems with hand-eye coordination, including difficulty writing and typing, as well as problems with her speech. A mental-status examination performed at that time showed a decreased fund of in-* IM denotes intramuscularly, and IV intravenously. formation, minor errors on a drawing of a threedimensional cube and on tests of mathematical skills, and reduced immediate recall on a wordlearning test. Her cranial nerves were normal. Her strength was intact, but she had mildly increased tone in her legs and hyperactive (3+) reflexes bilaterally. In December 2004, right-sided numbness developed and word-finding difficulty increased. The patient had difficulty carrying on a conversation and became increasingly forgetful. A neurologic examination revealed difficulty with expressive speech, with preserved comprehension, some right-left confusion, irregular saccadic eye movements, and increased tone on her right side. She received methylprednisolone (500 mg intravenously twice daily) from December 15 through 19, 2004. An MRI study performed on December 15 showed a large area of increased T 2 -weighted and decreased T 1 -weighted signal in the left frontal lobe posteriorly involving the subcortical white matter and extending into the centrum semiovale and corona radiata, without enhancement or mass effect (Fig. 1A) . A second area of abnormal signal was noted in the right posterior parietal lobe. On December 29, 2004, a right-sided hemiparesis with an extensor plantar response was noted. On January 5, 2005, the patient's condition was judged to be worse, with increasing right-sided hemiparesis and worsening nonfluent aphasia. Her right-arm strength was 0/5, and her right-leg strength was 2/5 proximally and 0/5 distally. On the assumption that her clinical deterioration represented an exacerbation of multiple sclerosis, she received another five-day course of methylprednisolone, beginning on January 5, 2005 (500 mg intravenously twice daily). Her last dose of natalizumab was given on January 18, 2005. On January 24, 2005, her white-cell count was 14,400 per cubic millimeter (77 percent neutrophils, 18 percent lymphocytes, 4 percent monocytes, and 1 percent eosinophils), with an absolute lymphocyte count of 2500 per cubic millimeter.
The patient's neurologic status continued to decline, and she was hospitalized on February 12, 2005. On admission, she was unresponsive, with a right-sided gaze preference. She had a marked spastic right-sided hemiplegia and some left-sided weakness. An MRI scan obtained on February 12 (Fig. 1B  and 1C ) showed a dramatic increase in the extent of the high T 2 -weighted and low T 1 -weighted signal abnormalities in the left hemisphere, with extension of the lesion to the frontal, parietal, and temporal lobes and across the corpus callosum to the right frontal lobe. New midbrain and pontine lesions were also present. There was no enhancement or mass effect. At admission, the patient had a whitecell count of 14,000 per cubic millimeter (77 percent neutrophils, 16 percent lymphocytes, 6 percent monocytes, and 1 percent eosinophils and basophils). Her absolute lymphocyte count was normal (2300 cells per cubic millimeter).
An plex virus was negative, as were tests for West Nile virus IgG and IgM, eastern equine encephalomyelitis virus IgG and IgM, Borrelia burgdorferi IgG and IgM, and cryptococcal antigen and stains and cultures for bacteria, fungi, and acid-fast bacilli. A test for serum antibody against human immunodeficiency virus (HIV) type 1 and 2 was nonreactive. CD4+ and CD8+ T-cell counts were not assessed, but at no time was either absolute or relative lymphopenia noted.
The treating neurologist suspected PML, and a cerebrospinal fluid sample sent to the Mayo Medical Laboratories (Rochester, Minn.) for JC virus PCR testing was positive. The patient died on February 24, 2005; she was 46 years old.
Postmortem examination showed bilateral aspiration pneumonia and cachexia. There was prominent sinus histiocytosis of the lymph nodes and possible depletion of CD8+ T cells in comparison with the levels of CD4+ T cells, probably owing to severe terminal debilitation. Examination of the bone marrow showed a clinically significant leftward shift in granulocytic maturation. All other systemic organs were histologically normal; no non-CNS opportunistic infections were found. Postmortem blood samples were not tested for JC virus DNA or antibody.
The formalin-fixed, 1140-g brain was fluctuant on palpation over a large portion of the anterior left hemisphere; no discoloration or meningeal opacification was present. On coronal sectioning, this softened area corresponded to massive, coalescent areas of severe cavitation involving most of the left frontoparietal white matter, leaving only a ribbonlike strip of intact overlying cortex (Fig. 1D) . Smaller, noncavitated, ovoid areas of discoloration, a typical feature of PML, studded the remaining lefthemispheric white matter, particularly at the junctions between cortical gray matter and white matter, and involved the right superior frontal gyrus ( Fig.  2A) . A 7-mm lesion was identified in the left cerebral peduncle (Fig. 2B and 2C) . No multiple-sclerosis plaques were discernible in the corona radiata.
The brain stem, spinal cord, and optic chiasm were submitted in toto for histologic examination. Sections (total, 73 blocks) from the brain and spinal cord were stained with hematoxylin and eosin, with one fourth of the sections also stained with Luxol fast blue and periodic acid-Schiff for myelin. All sections were devoid of acute anoxic injury and vasculitis. Areas of PML showed near-total loss of myelin, an influx of macrophages, and numerous reactive astrocytes, but no perivascular or parenchymal lymphocytic inflammation (Fig. 2D) . Astrocytes with bizarre, enlarged hyperchromatic nuclei, a typical finding in PML, were common, even in smaller lesions (Fig. 2D ). There were large numbers of oligodendrocytes with the classic violaceous intranuclear inclusions of PML (Fig. 2E) . Cells with inclusions had a strong positive signal for JC virus DNA on in situ hybridization (probe 40847, Enzo Life Sciences) (Fig. 2F) .
In addition to the PML lesions seen on gross examination, myriad minute lesions were easily identified microscopically in virtually every section examined from the left cerebral hemisphere, as well as in most of the sections from the right side and all of the brain-stem sections. PML was found only focally in the cerebellum; no granule-cell depletion was seen. The optic nerve, chiasm, and spinal cord contained neither PML lesions nor multiple-sclerosis demyelinating lesions. Examination of the spinal cord showed unilateral wallerian degeneration that was due to the cavitated lesions involving the left motor strip and internal capsule. Remote cortical microinfarctions were found in the right superior frontal and parietal gyri and splenium of the corpus callosum.
PML is a demyelinating disease of the CNS caused by lytic infection of oligodendrocytes by JC polyomavirus. Primary JC virus infection occurs in childhood and is asymptomatic. JC virus antibodies are detectable in approximately 50 to 70 percent of the adult population. 3, 4 After the primary infection, JC virus remains latent in kidneys and lymphoid organs. Up to 64 percent of healthy adults have shedding of JC virus in urine in the absence of any clinical symptoms, suggesting that asymptomatic active JC virus infection is common in immunocompetent persons. 5 In contrast, PML occurs almost exclusively in immunocompromised persons, particularly those with depressed cell-mediated immunity resulting from HIV infection, hematologic cancers, or immunosuppressive medications. 1 In recipients of bone marrow transplants, PML has also been associated with treatment with rituximab, an antibody against CD20 expressed on B cells, 6 and cases of PML-like CNS demyelinating illness have been reported in patients with rheumatic diseases treated . with antagonists of tumor necrosis factor a . 7 Although multiple sclerosis is an immune-mediated disorder, to our knowledge, patients with multiple sclerosis have not previously been identified as at increased risk for PML. Natalizumab is a humanized monoclonal antibody against a 4 integrins that was approved by the Food and Drug Administration for the treatment of several immune-mediated disorders, including multiple sclerosis and inflammatory bowel disease. [8] [9] [10] Antibodies against a 4 integrins inhibit the binding of cells expressing a 4 b 1 integrin and a 4 b 7 integrin (e.g., lymphocytes) to vascular-cell adhesion molecule 1 and mucosal addressin-cell adhesion molecule 1 on endothelial cells, a critical step in the diapedesis of lymphocytes across blood vessels into the CNS and mucosal organs. 10, 11 Treatment with antibodies against a 4 integrins prevents inflammatory cells from crossing the blood-brain barrier and inhibits the accumulation of immune cells in the CNS in animals with experimental allergic encephalomyelitis. [11] [12] [13] Our patient received interferon beta-1a for nearly five years and received combined therapy with natalizumab and interferon beta-1a for just over two years as part of the SENTINEL trial. We therefore cannot rule out a potential contributory role of interferon beta-1a in the genesis of this patient's PML.
However, to date, there have been no reported cases of PML in patients receiving interferon beta-1a monotherapy.
The diagnosis of PML was established on the basis of a positive PCR assay for JC viral DNA in cerebrospinal fluid in a patient with clinical and neuroimaging findings that were typical of PML, and the diagnosis was confirmed at autopsy. The severity and extent of disease were dramatic. Nearly every tissue section from bilateral cerebral hemispheres that we examined had either macroscopic or microscopic PML lesions, ranging from minute to massive in size. There was extensive tissue destruction and cavitation in the left frontoparietal area, and the lesions contained large numbers of oligodendrocytes with inclusions. No inflammatory response was present. Although no formal quantitation was performed, the extent of the PML involvement was similar to or exceeded that seen in HIV-infected patients before the advent of highly active antiretroviral therapy.
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